On May 22, 2025, Merus N.V. reported promising interim clinical results from a Phase 2 trial of its bispecific antibody petosemtamab, showing a 63% overall response rate among 43 evaluable patients treated. The median progression-free survival was recorded at 9 months, with a 79% overall survival rate at 12 months, and the treatment was generally well tolerated.